Musiani P, Lauriola L, Piantelli M
Clin Chim Acta. 1978 Apr 3;85(1):61-6. doi: 10.1016/0009-8981(78)90101-8.
Complexes between alpha-1-antitrypsin (alpha 1AT) and monoclonal IgA are regularly demonstrable in the plasma of myeloma patients. These alpha 1AT-IgA complexes, free of contamination by unbound alpha 1AT, are purified from 5 myeloma patients sera using salt-mediated hydrophobic chromatography. The complexes have a molecular weight greater than or equal to 400 000: this suggests that alpha 1AT is bound to di- or polymeric IgA. The alpha 1AT bound to IgA constitutes the 3.2, 3.5, 7.2, 8.5, and 24.6 per cent of the total alpha 1AT present in the 5 myeloma serum samples. There is a linear correlation between bound alpha 1AT concentration and IgA level in the range of the IgA concentrations considered (r = 0.988; p less than 0.05). Similar values are obtained quantitating bound alpha 1AT by radioimmunodiffusion technique or by determination of the trypsin-inhibiting capacity; this demonstrates that the bound alpha 1AT fully retains its inhibitory capacity. The biological significant of this binding phenomenon is discussed.
在骨髓瘤患者的血浆中经常能检测到α-1抗胰蛋白酶(α1AT)与单克隆IgA之间的复合物。这些不含未结合α1AT污染的α1AT-IgA复合物,是使用盐介导的疏水色谱法从5例骨髓瘤患者的血清中纯化得到的。这些复合物的分子量大于或等于400000:这表明α1AT与二聚体或多聚体IgA结合。与IgA结合的α1AT占5例骨髓瘤血清样本中总α1AT的3.2%、3.5%、7.2%、8.5%和24.6%。在所考虑的IgA浓度范围内,结合的α1AT浓度与IgA水平之间存在线性相关性(r = 0.988;p < 0.05)。通过放射免疫扩散技术或通过测定胰蛋白酶抑制能力来定量结合的α1AT,可得到相似的值;这表明结合的α1AT完全保留了其抑制能力。本文讨论了这种结合现象的生物学意义。